HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Sees Large Drop in Short Interest

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) was the target of a significant decline in short interest in the month of March. As of March 13th, there was short interest totaling 278,317 shares, a decline of 13.7% from the February 26th total of 322,619 shares. Approximately 0.2% of the shares of the company are short sold. Based on an average daily volume of 27,811 shares, the short-interest ratio is currently 10.0 days.

Hedge Funds Weigh In On HUTCHMED

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its holdings in shares of HUTCHMED by 8.5% during the first quarter. Goldman Sachs Group Inc. now owns 93,919 shares of the company’s stock worth $1,413,000 after buying an additional 7,342 shares in the last quarter. Jane Street Group LLC raised its stake in shares of HUTCHMED by 128.0% in the first quarter. Jane Street Group LLC now owns 222,241 shares of the company’s stock valued at $3,343,000 after acquiring an additional 124,771 shares during the last quarter. Tema Etfs LLC acquired a new position in shares of HUTCHMED in the 2nd quarter worth approximately $641,000. Ameriprise Financial Inc. boosted its holdings in shares of HUTCHMED by 4.7% in the 2nd quarter. Ameriprise Financial Inc. now owns 15,519 shares of the company’s stock worth $234,000 after acquiring an additional 698 shares in the last quarter. Finally, Bank of America Corp DE grew its position in HUTCHMED by 17.3% during the 2nd quarter. Bank of America Corp DE now owns 20,582 shares of the company’s stock worth $310,000 after acquiring an additional 3,035 shares during the last quarter. 8.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on HCM shares. Jefferies Financial Group raised HUTCHMED to a “strong-buy” rating in a research report on Monday, January 19th. Wall Street Zen cut shares of HUTCHMED from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of HUTCHMED in a report on Thursday, January 22nd. Finally, Bank of America decreased their target price on shares of HUTCHMED from $21.00 to $20.00 and set a “buy” rating on the stock in a research report on Tuesday, March 10th. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, HUTCHMED currently has an average rating of “Hold” and a consensus price target of $16.88.

HUTCHMED Stock Performance

HUTCHMED stock traded up $0.16 during mid-day trading on Wednesday, hitting $15.12. 5,209 shares of the company were exchanged, compared to its average volume of 36,778. The business has a fifty day moving average of $14.59 and a 200 day moving average of $14.77. HUTCHMED has a 1-year low of $11.51 and a 1-year high of $19.50. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.83 and a current ratio of 4.96.

HUTCHMED (NASDAQ:HCM) last issued its earnings results on Friday, March 6th. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $2.50 by ($2.49). The firm had revenue of $135.42 million for the quarter, compared to the consensus estimate of $290.50 million. Equities analysts predict that HUTCHMED will post 0.16 EPS for the current fiscal year.

About HUTCHMED

HUTCHMED (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer.